“Ultimovacs has announced being granted Orphan Drug Designation by the FDA for its universal cancer vaccine UV1 in the treatment […]
Other News |
Press Releases
Biostock interview: “Ultimovacs reaches key milestones with UV1”
“Norwegian Ultimovacs has made some big announcements recently, including discussions for a fifth phase II clinical trial with universal cancer […]
Biostock article: “Ultimovacs launches fifth phase II trial with UV1”
“Norwegian Ultimovacs continues to expand its clinical development pipeline with universal cancer vaccine UV1. This week, the company announced its […]
HealthTalk article: “Ultimovacs tester ut prostakreftvaksine utviklet på ny kreftvaksineplattform”
“Ultimovacs jakter nå på nye kreftvaksinekandidater basert på en innovativ, ny vaksineteknologi. Norske pasienter som har fått tilbakefall etter at […]
Ultimovacs hits the front page in Finansavisen 14.10.2021
HealtTalk article: “Ultimovacs med lovende 2-års overlevelsesdata: 80 prosent av pasientene lever etter 2 år”
“Ultimovacs har gått ut med 2-års overlevelsesdata fra sin fase-1 studie der nydiagnostiserte pasienter med metastatisk føflekkreft fikk kreftvaksinen UV1 […]
BioStock article on the Positive phase I data for Ultimovacs
“Biotech company Ultimovacs continues to strengthen the clinical evidence for its universal cancer vaccine UV1. On Wednesday morning the company […]
Two Key Appointments to the Management Team as the Operations Advances
Ultimovacs ASA today announced two senior appointments to its management team: Orla Mc Callion as Head of Regulatory Affairs & […]
Biostock article on the TENDU trial and the TET-platform
“Ultimovacs’ TENDU trial is a clinical phase I study aimed at testing the company’s TET platform for cancer vaccine development […]
Finansavisen – Topline results
Read the Finansavisen article (in Norwegian) here